Published in
Impact Journals, Oncotarget, 15(6), p. 13462-13475, 2015
Links
- Impact Journals
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
Journal article published in 2015 by
Julie Jacobs,
Karen Zwaenepoel,
Christian Rolfo,
Jolien Van den Bossche,
Jolien Van den Bossche 
,
Christophe Deben,
Karen Silence,
Christophe Hermans,
Evelien Smits,
Paul Van Schil,
Paul Van Schil,
Filip Lardon,
Vanessa Deschoolmeester,
Patrick Pauwels
,
Christophe Deben,
Karen Silence,
Christophe Hermans,
Evelien Smits,
Paul Van Schil,
Paul Van Schil,
Filip Lardon,
Vanessa Deschoolmeester,
Patrick Pauwels
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Although normally restricted to activated T and B cells and mature dendritic cells, constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid tumors, where it increases tumor cell and regulatory T cell survival by signaling through its receptor, CD27.